New antibody drug targets deadly heart shock in early trial
Disease control
Recruiting now
This early-stage trial tests a new antibody drug called procizumab in 130 people with cardiogenic shock, a life-threatening condition where the heart cannot pump enough blood. The drug blocks a protein called DPP3, which is linked to worse outcomes. The main goal is to check safe…
Phase: PHASE1, PHASE2 • Sponsor: 4TEEN4 Pharmaceuticals GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC